Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer
Publication
, Other
Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Hsu, DS ...
April 3, 2023
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Somarelli, J. A., Roghani, R. S., Moghaddam, A. S., Thomas, B. C., Rupprecht, G., Ware, K. E., … Hsu, D. S. (2023). Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. https://doi.org/10.1158/1535-7163.22521145
Somarelli, Jason A., Roham Salman Roghani, Ali Sanjari Moghaddam, Beatrice C. Thomas, Gabrielle Rupprecht, Kathryn E. Ware, Erdem Altunel, et al. “Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer,” April 3, 2023. https://doi.org/10.1158/1535-7163.22521145.
Somarelli JA, Roghani RS, Moghaddam AS, Thomas BC, Rupprecht G, Ware KE, et al. Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. 2023.
Somarelli, Jason A., et al. Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. 3 Apr. 2023. Crossref, doi:10.1158/1535-7163.22521145.
Somarelli JA, Roghani RS, Moghaddam AS, Thomas BC, Rupprecht G, Ware KE, Altunel E, Mantyh JB, Kim SY, McCall SJ, Shen X, Mantyh CR, Hsu DS. Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. 2023.